Avonex-evaluation of Quality of Life and Convenience in Belgian Participants - The AVAIL Study

• Status: Completed
• Trial end date: 2015-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective is to assess the quality of life of intramuscular (IM) Interferon Beta-1a in participants with relapsing remitting multiple sclerosis (RRMS) or Clinically Isolated Syndrome (CIS) in a clinical practice setting.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Biogen
• Treatments: Interferon beta-1a; Interferon-beta; Interferons

Criteria

Key Inclusion Criteria:

• Decision to treat with Interferon Beta-1a (IFN beta-1a) must precede enrollment, independently of the study and in compliance with the marketing authorization

• Study enrollment must occur prior to 4th weekly administration of IFN beta-1a

• Able to understand and complete a self-administered questionnaire

• No contra-indications for IFN beta-1a

Key Exclusion Criteria:

• Subjects with history of hypersensitivity to natural or recombinant IFN beta or to any component

• Subjects with primary or secondary progressive MS

• Subjects with current severe depression and/or suicidal ideation

• Pregnant women

• Subjects participating in another clinical trial

• Subjects who do not want to participate in the study

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.